Trimethoprim and rifampin in combination for chemoprophylaxis of household contacts of patients with invasive infections due to Haemophilus influenzae type b

Antimicrob Agents Chemother. 1983 Nov;24(5):658-62. doi: 10.1128/AAC.24.5.658.

Abstract

We compared the effectiveness of rifampin-trimethoprim in fixed combination (3.75:1) to rifampin alone in the eradication of Haemophilus influenzae type b carriage among contacts of patients with invasive infection caused by this organism. The study population was composed of 127 index patients and 620 contacts. Twenty-six percent of contacts were colonized. Rifampin-trimethoprim eradicated carriage in 77.6% of contacts (71.1% in contacts less than 5 years, 84.2% in contacts greater than or equal to 5 years) whereas rifampin eradicated carriage in 69.9% of contacts (56.4% in contacts less than 5 years, 81.8% in contacts greater than or equal to 5 years). A single isolate resistant to rifampin and rifampin-trimethoprim was encountered. The eradication rate achieved with this regimen of rifampin-trimethoprim was too low to recommend its routine use. However, a higher dose or longer course might merit clinical trial.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Carrier State
  • Haemophilus Infections / microbiology
  • Haemophilus Infections / prevention & control*
  • Haemophilus influenzae / drug effects
  • Humans
  • Microbial Sensitivity Tests
  • Patient Compliance
  • Rifampin / adverse effects
  • Rifampin / therapeutic use*
  • Trimethoprim / adverse effects
  • Trimethoprim / therapeutic use*

Substances

  • Trimethoprim
  • Rifampin